MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
577.30
-8.91
-1.52%
After Hours: 577.30 0 0.00% 17:01 12/05 EST
OPEN
585.39
PREV CLOSE
586.21
HIGH
593.00
LOW
573.00
VOLUME
220.91K
TURNOVER
--
52 WEEK HIGH
605.00
52 WEEK LOW
265.00
MARKET CAP
13.11B
P/E (TTM)
-44.3838
1D
5D
1M
3M
1Y
5Y
1D
Is Madrigal Pharmaceuticals Stock Still Attractive After Its 798% Three Year Surge?
Simply Wall St · 21h ago
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company
Seeking Alpha · 2d ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Barchart · 2d ago
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Reuters · 2d ago
Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares
Reuters · 2d ago
A Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Launch and Pipeline Progress
Simply Wall St · 3d ago
ValuEngine Weekly Market Summary And Commentary
Seeking Alpha · 4d ago
Weekly Report: what happened at MDGL last week (1124-1128)?
Weekly Report · 5d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.